Literature DB >> 26973098

Metabolically Stabilized (68)Ga-NOTA-Bombesin for PET Imaging of Prostate Cancer and Influence of Protease Inhibitor Phosphoramidon.

Susan Richter1, Melinda Wuest1, Cody N Bergman1, Stephanie Krieger2, Buck E Rogers2, Frank Wuest1.   

Abstract

Peptide receptor-based targeted molecular imaging and therapy of cancer is on the current forefront of nuclear medicine preclinical research and clinical practice. The frequent overexpression of gastrin-releasing peptide (GRP) receptors in prostate cancer stimulated the development of radiolabeled bombesin derivatives as high affinity peptide ligands for selective targeting of the GRP receptor. In this study, we have evaluated a novel (68)Ga-labeled bombesin derivative for PET imaging of prostate cancer in vivo. In addition, we were interested in testing the recently proposed "serve-and-protect" strategy to improve metabolic stability of radiolabeled peptides in vivo and to enhance tumor uptake. GRP receptor targeting peptides NOTA-BBN2 and (nat)Ga-NOTA-BBN2 demonstrated a characteristic antagonistic profile and high binding affinity toward the GRP receptor in PC3 cells (IC50 4.6-8.2 nM). Radiolabeled peptide (68)Ga-NOTA-BBN2 was obtained from NOTA-BBN2 in radiochemical yields greater than 62% (decay-corrected). Total synthesis time was 35 min, including purification using solid-phase extraction. (68)Ga-NOTA-BBN2 exhibited favorable resistance against metabolic degradation by peptidases in vivo within the investigated time frame of 60 min. Interestingly, metabolic stability was not further enhanced in the presence of protease inhibitor phosphoramidon. Dynamic PET studies showed high tumor uptake in both PC3- and LNCaP-bearing BALB/c nude mice (SUV5min > 0.6; SUV60min > 0.5). Radiotracer (68)Ga-NOTA-BBN2 represents a novel radiometal-based bombesin derivative suitable for GRP receptor targeting in PC3 and LNCaP mouse xenografts. Further increase of metabolic stability in vivo and enhanced tumor uptake were not observed upon administration of protease inhibitor phosphoramidon. This led to the conclusion that the recently proposed "serve-and-protect" strategy may not be valid for peptides exhibiting favorable intrinsic metabolic stability in vivo.

Entities:  

Keywords:  68Ga; PET; bombesin; gastrin-releasing peptide (GRP) receptor; phosphoramidon; prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 26973098     DOI: 10.1021/acs.molpharmaceut.5b00970

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  8 in total

Review 1.  Radiolabeled bombesin derivatives for preclinical oncological imaging.

Authors:  Carolina de Aguiar Ferreira; Leonardo Lima Fuscaldi; Danyelle M Townsend; Domenico Rubello; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2016-12-29       Impact factor: 6.529

2.  Water-Soluble Chitosan Conjugated DOTA-Bombesin Peptide Capped Gold Nanoparticles as a Targeted Therapeutic Agent for Prostate Cancer.

Authors:  Theeranan Tangthong; Thananchai Piroonpan; Velaphi C Thipe; Menka Khoobchandani; Kavita Katti; Kattesh V Katti; Wanvimol Pasanphan
Journal:  Nanotechnol Sci Appl       Date:  2021-03-18

3.  68Ga-Labeled [Leu13ψThz14]Bombesin(7-14) Derivatives: Promising GRPR-Targeting PET Tracers with Low Pancreas Uptake.

Authors:  Lei Wang; Zhengxing Zhang; Helen Merkens; Jutta Zeisler; Chengcheng Zhang; Aron Roxin; Ruiyan Tan; François Bénard; Kuo-Shyan Lin
Journal:  Molecules       Date:  2022-06-11       Impact factor: 4.927

Review 4.  Good practices for 68Ga radiopharmaceutical production.

Authors:  Bryce J B Nelson; Jan D Andersson; Frank Wuest; Sarah Spreckelmeyer
Journal:  EJNMMI Radiopharm Chem       Date:  2022-10-22

Review 5.  Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers.

Authors:  David G Calatayud; Sotia Neophytou; Eleni Nicodemou; S Giuseppe Giuffrida; Haobo Ge; Sofia I Pascu
Journal:  Front Chem       Date:  2022-04-12       Impact factor: 5.545

6.  Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications.

Authors:  Mehdi Azizi; Hassan Dianat-Moghadam; Roya Salehi; Masoud Farshbaf; Disha Iyengar; Samaresh Sau; Arun K Iyer; Hadi Valizadeh; Mohammad Mehrmohammadi; Michael R Hamblin
Journal:  Adv Funct Mater       Date:  2020-03-03       Impact factor: 18.808

7.  Identification of a Suitable Peptidic Molecular Platform for the Development of NPY(Y1 )R-Specific Imaging Agents.

Authors:  Korbinian Krieger; Björn Wängler; Ralf Schirrmacher; Carmen Wängler
Journal:  ChemMedChem       Date:  2020-08-07       Impact factor: 3.466

Review 8.  Dual Probes for Positron Emission Tomography (PET) and Fluorescence Imaging (FI) of Cancer.

Authors:  Richard Yuen; Frederick G West; Frank Wuest
Journal:  Pharmaceutics       Date:  2022-03-15       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.